Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease

REFERENCES

• Department of Health and Human Services (DHHS). Guide-lines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2005. Available at: http://aidsinfo.nih.gov/guidelines. Accessed October 10, 2005.
   Google Scholar
• Gulick RM, Mellors JW, Haylir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133:35–39.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Haylir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280:35–41.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. 200115: 2379–2384.
   Google Scholar
• Moore R, Keruly J, Gebo K, Lucas G. Improvement in virologic, immunologic, and clinical outcomes in clinical practice from 1996 to 2002. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Francisco. Abstract 558.
   Google Scholar
• Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375–1384.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Mellors JW. Antiretroviral therapy for previ-ously treated patients. N Engl J Med. 2001;345:452–455.
   PubMed Web of Science ®Google Scholar
• Greenberg ML, Sista P, MiraIles GD, et al. Enfuvirtide (T-20) and T-1249 resistance: observations from Phase ll clinical trials of enfuvirtide in combination with oral antiretrovirals and a Phase I/II dose-ranging monotherapy trial of T-1249. In: Program and abstracts of the XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Impli-cations; June 8–11, 2004; Seville, Spain. Abstract 128.
   Google Scholar
• Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–2185.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195.
   PubMed Web of Science ®Google Scholar
• Katlama C, Arastéh K, Clotet B, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. In: Program and abstracts of the 2nd International AIDS Soci-ety Meeting; July 13–16, 2003; Paris, France. Abstract LB2.
   Google Scholar
• Trottier B, Arasteh K, Henry K, et al. Durability of response to enfuvirtide through 48 weeks in the TORO trials. In: Program and abstracts of the 43rd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy; Sep-tember 14–17, 2003; Chicago, IL. Abstract H–835.
   Google Scholar
• Eron J, Delfraissy JF, Kuritzkes D, et al. Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, IL. Abstract H–836.
   Google Scholar
• Arasteh K, Lazzarin A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evalua-tion of enfuvirtide with an optimized background regimen. In: Program and abstracts of the XV International AIDS Conference; July 11–16, 2004; Bangkok, Thailand.
   Google Scholar
• Walmsley S, Clotet B, Cooper D, Lalezari J, Nelson M, et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials. In: Program and abstracts of the 9th European AIDS Conference; October 25–29, 2003; Warsaw, Poland. Abstract 7.3/15.
   Google Scholar
• Cahn P. for the RESIST-2 study team. 24-week data from RESIST-2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimised ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomised multicentre trial in treatment-experienced HIV+ patients. In: Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection; UK; Glasgow. Abstract PL14.3.
   Google Scholar
• Hicks C. for the RESIST-1 study team. RESIST-1: a phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized com-parator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. In: Program and abstracts of the 44th Interscience Conference on Anti-microbial Agents and Chemotherapy; October 30—Novem-ber 2, 2004; Washington, DC. Abstract H–1137a.
   Google Scholar
• Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment op-tions: 24-week planned interim analysis of 2 96-week mul-tinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston, MA. Abstract 164LB.
   Google Scholar
• US Food and Drug Administration, Center for Drug Evalua-tion and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical con-siderations for accelerated and traditional approval. 2002. Available at: http://www.fda.gov/cder/guidance/3647fn1.pdf. Accessed August 29, 2003.
   Google Scholar
• Deeks SG, Hellmann N, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immu-nodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phe-notypic drug susceptibility with virologic outcome. J Infect 0is. 2005;179: 1375–1381.
   Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
   PubMed Web of Science ®Google Scholar
• Tierney C, Lathey JL, Christopherson C, et al. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients re-ceiving nucleoside therapy. J Infect Dis. 2003;187:144–148.
   PubMed Web of Science ®Google Scholar
• Haubrich R, DeMasi R, Thommes JA. Improved virologic response in three-class experienced patients when an ac-tive boosted protease inhibitor is combined with enfuvirtide (ENF). In: Program and abstracts of the 43rd Infectious Diseases Society of America Annual Meeting; October 6–9, 2005; San Francisco, CA. Poster 785.
   Google Scholar
• Cooper D, Hicks C, Cahn P, et al. 24-week RESIST study analyses: The efficacy of tipranavir/ritonavir (TPV/r) is su-perior to lopinavir/ritonavir (LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR). In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston, MA. Poster 560.
   Google Scholar